Akamis Bio

BiotechnologySeries CCambridge, USakamisbio.com

Latest round

Series C

Last raised

May 2015

Total raised

$73M

Investors

7

About Akamis Bio

Founded in 2010 in Cambridge, US, Akamis Bio Limited focuses on developing T-SIGn® therapeutics for cancer treatment. The CEO is Howard Davis, and the founder is Kerry Fisher, who has a history of founding other ventures.Akamis Bio specializes in Tumor-Specific Immuno-Gene (T-SIGn®) therapeutics, with its primary product, NG-350A, currently in Phase 1b clinical trials. This immuno-stimulatory tumor gene therapy promotes intratumoral expression of a CD40 agonist monoclonal antibody, aiming to help the immune system recognize and eliminate cancer cells in various solid tumors.80. The company aims to enhance its product pipeline and expand its reach into new markets, with a strategic focus on collaboration with healthcare providers and institutions to advance its innovative cancer therapies.

Who invested in Akamis Bio

7 investors across 2 rounds

See all investors in Akamis Bio

Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.

Funding rounds

  1. Series C

    May 19, 2015

    Amount

    $39M

    Investors

    Locked

  2. Series B

    Jul 5, 2012

    Amount

    $34M

    Investors

    Locked

Questions about Akamis Bio

Who invested in Akamis Bio?

Akamis Bio has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.

How much funding has Akamis Bio raised?

Akamis Bio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.

When did Akamis Bio last raise money?

Akamis Bio's most recent round on record is a Series C, in May 2015.

What does Akamis Bio do?

Founded in 2010 in Cambridge, US, Akamis Bio Limited focuses on developing T-SIGn® therapeutics for cancer treatment.

Where is Akamis Bio headquartered?

Akamis Bio is headquartered in Cambridge, US.

Which VCs invest in companies like Akamis Bio?

Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Akamis Bio's stage. Their profiles are linked below.

Raising like Akamis Bio? Find the right VCs.

Capital Atlas matches your startup to active investors by stage, sector and region.

Free to start. Upgrade when you're ready to reach out.